title: Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
abstract: Sorafenib is an orally administered active multikinase inhibitor for metastatic renal cell carcinoma that is now considered a standard agent. Skin toxicity, such as hand-foot skin reaction, is one of the frequent adverse effects of sorafenib. On the other hand, sorafenib-induced erythema multiforme is very rare, and Stevens-Johnson syndrome and toxic epidermal necrolysis induced by sorafenib have not been reported. We report the first case of Stevens-Johnson syndrome caused by sorafenib for metastatic renal cell carcinoma.
authors: Departments of Urology and Dermatology, Kitasato University School of Medicine, Sagamihara, Japan.
authors: Masaomi
authors: M
authors: Ikeda
authors: Tetsuo
authors: T
authors: Fujita
authors: Yasuyuki
authors: Y
authors: Amoh
authors: Sumiyuki
authors: S
authors: Mii
authors: Kazumasa
authors: K
authors: Matsumoto
authors: Masatsugu
authors: M
authors: Iwamura
mesh_terms: D000368:Aged; D001623:Betamethasone / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects; D000077157:Sorafenib; D013262:Stevens-Johnson Syndrome / Q000150:complications / Q000473:pathology*
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; C401859:temsirolimus; D001623:Betamethasone; D011239:Prednisolone; D000077157:Sorafenib; D020123:Sirolimus